The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shanta Somani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mrs. Shanta Somani, a member of the promoter/promoter group, filed a revised disclosure under SEBI SAST Regulation 29(2) for an open market sale of 48,781 equity shares (3.25% stake) in Chemo Pharma Laboratories Limited on 18 July 2025. The revision only adds the sale date that was missing in the original filing. After this sale, her holding in the company has dropped to zero, meaning she has fully exited her shareholding in the target company.
This represents a complete exit by a promoter-group member, reducing promoter alignment in the stock. For existing shareholders, a promoter fully selling out their stake is generally viewed negatively as it signals loss of insider confidence in future value.